Member Info for Matml74

“ Avacta should have at least included the MHRA and patients in the UK in this study.”

Exactly. The hospitals were set up to take patients. Incompetent trial management and a large waste of funds.

Only 27m of the 52m placing shares have been issued. The rest need to get approved along with REX at the EGM.

Will be interesting to see what happens after EGM.

Great post. The only sensible thing written on this board in a very long time.

Load of rubbish. Establishing an MTD and optimum dose is essential for drug development. It’s not the methodology that has been wrong, as the company is seeing efficacy signals at higher doses as well so who is to say lower more often is better without the data for higher doses.

Questions around speed of recruitment should be asked. Some cohorts have taken an exceptionally long time.

Also the company has gone from recruiting in 2 countries to just the US without providing an explanation. This will impact speed of recruitment in P2 and future studies.

Communication on the current situation and future plans is poor with everyone currently using a T&P broker note to guess the future written by an analyst that got the mechanism of Precision wrong and who is not a pharma specialist.

Time for the company to have a serious conversation with investors about this IMO rather than hiding away.

“minimise dilution at this level”

is alan taking the **** or what. what a ******* insult from a guy who couldn’t get a licence deal across the line which would have ensured no dilution at this level.

What are you talking about? They convert them and then sell them….. every quarter. The terms of the CLN mean they can’t lose, they now just get more to sell.

If they backed the company they would own well over 3% by now.

“ because they could also convert the entire bond into shares at anytime as well to get a critical mass of shares against retail”

Your presuming that Heights would back the company and hold the shares which seems unlikely given the quarterly shares sales and lack of TR1. Heights equally could accept the offer and run off into the hills quids in.

If Avacta had of privately placed the whole amount with an institution or large pharma I would have bought the defending a low ball offer line.

However at this point it appears not to be the case. Let’s see if anyone has taken 3% or more and issues a TR1.

it’s this ****ty site. has happened to a few of my posts.

Great post Cindercone. My thoughts exactly!

The silence these past two days is very disappointing from the company.

If only the CEO would have the decency to come out and explain their development pathway for ava6000. Pathetic.

why would they give two ****s about us regulations?

they are listed in the uk so tell me why any us regulations would apply.

as not speaking for two days after this ****show placing shows the true character of the man to me. i expected at least an explanation of the haphazard development plan that has been put in front of shareholders.

AS really should have come out today and explained it clearly for everyone to understand.

Poor form.

3996 was meant to be in the clinic this quarter.

A proper biotech with this platform would have half a dozen compounds in the pipeline at pre clinical or in the clinic.

This funding is pitiful in the big scheme of things. It’s a cash runway for one drug.

AS is playing a very long game!

He must go and Avacta need to get the technology into a large pharma that can actually develop a serious pipline of drugs!

Luke,

P3 will be required for all indications where doxorubicin is not SOC so I think you are looking at it slightly the wrong way.

STS should still be pivotal at P2 and should be commercialised earlier.

It is one of the positive’s in this rns that the company now appears to be widening the indications that they plan on using ava6000 for.

It’s new. Last year they did away with the dose expansion and were focusing on STS only and pivotal P2.

Now they have added dose expansion prior to P2. It appears they think AVA can challenge for other indications.

Problem is this raise doesn’t get them close to funding and expanded P2 let alone a P3 for indications with other SOC’s.

Many questions need to be answered!

‘anticipate commencing a potential Phase 3 trial in Q1 2026 for AVA6000 (also subject to funding and regulatory approval).’

I think he was quoted as saying we wouldn’t need a P3 trial?

Phase 3 will not be required where AVA6000 is being compared to doxorubicin ie. with an indication like STS.

However they are now conduction an expansion study (they weren’t previously doing this in H2).

If they want to trial indications like breast cancer/pancreatic etc where doxorubicin is not standard of care then phase 3 trials will be required to determine if AVA is a better option than current SOC.

" only the company itself knows which is true and it has a responsibility in my opinion to now issue an rns if the rumours are false"

**** me they would be putting out an rns every week if they did that for every social media rumour..... which is what this is!

twitter is a ****hole of manipulation and rumours coming from that platform are not worthy of response by any company.

tw is an obvious manipulator, been wrong previously in this regard and not deemed financial press so would be a disgrace if they rns'd in response to that.

charles archer is a wannabe trader masquerading as a financial writer so zero need to respond there.

if the' raise' rumour was stated in the ft or any other any other reputable financial press then yes the company should respond rns.

understand this for what it is. a small short/trading group/s manipulating the market in a period of silence. for lth it is a gift. for the shooters and traders they will make a few percent here and there so good luck to them.

Charles Archer is just another wannabe twitter/IG stock analyst/trader.

That is a one month closed period!

28th Feb buy …… 30th March results.

It’s a closed period before results.